Zacks: Brokerages Anticipate Syros Pharmaceuticals Inc (NASDAQ:SYRS) Will Announce Earnings of -$0.45 Per Share

Analysts expect Syros Pharmaceuticals Inc (NASDAQ:SYRS) to report ($0.45) earnings per share for the current quarter, Zacks reports. Five analysts have provided estimates for Syros Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.35) and the lowest estimate coming in at ($0.54). Syros Pharmaceuticals reported earnings per share of ($0.49) in the same quarter last year, which suggests a positive year over year growth rate of 8.2%. The business is scheduled to issue its next quarterly earnings report on Wednesday, May 6th.

On average, analysts expect that Syros Pharmaceuticals will report full year earnings of ($1.81) per share for the current financial year, with EPS estimates ranging from ($1.98) to ($1.40). For the next financial year, analysts forecast that the company will report earnings of ($1.92) per share, with EPS estimates ranging from ($2.46) to ($1.60). Zacks’ EPS calculations are an average based on a survey of research firms that follow Syros Pharmaceuticals.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its earnings results on Thursday, March 5th. The company reported ($0.46) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.47) by $0.01. Syros Pharmaceuticals had a negative net margin of 3,806.16% and a negative return on equity of 86.29%. The firm had revenue of $0.51 million during the quarter, compared to the consensus estimate of $0.79 million.

Several equities research analysts recently commented on the stock. ValuEngine upgraded shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, February 25th. Wedbush cut Syros Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $9.00 price target on the stock. in a research report on Friday, January 17th. BidaskClub cut Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, January 31st. Cowen reiterated a “buy” rating on shares of Syros Pharmaceuticals in a research report on Thursday, March 5th. Finally, HC Wainwright reiterated a “neutral” rating and set a $8.00 price target (down from $10.00) on shares of Syros Pharmaceuticals in a research report on Friday, March 6th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company. Syros Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $12.54.

SYRS opened at $5.67 on Tuesday. The company’s 50 day moving average is $6.40 and its 200-day moving average is $6.99. Syros Pharmaceuticals has a 1-year low of $4.26 and a 1-year high of $11.93. The company has a debt-to-equity ratio of 0.31, a quick ratio of 4.87 and a current ratio of 4.87.

A number of hedge funds have recently made changes to their positions in SYRS. Tower Research Capital LLC TRC lifted its holdings in shares of Syros Pharmaceuticals by 863.4% in the third quarter. Tower Research Capital LLC TRC now owns 2,688 shares of the company’s stock worth $28,000 after buying an additional 2,409 shares in the last quarter. Bank of Montreal Can increased its stake in Syros Pharmaceuticals by 44.6% during the fourth quarter. Bank of Montreal Can now owns 4,400 shares of the company’s stock worth $30,000 after acquiring an additional 1,357 shares during the last quarter. Citigroup Inc. increased its stake in Syros Pharmaceuticals by 175.0% during the fourth quarter. Citigroup Inc. now owns 10,236 shares of the company’s stock worth $71,000 after acquiring an additional 6,514 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in Syros Pharmaceuticals during the fourth quarter worth $77,000. Finally, Trexquant Investment LP acquired a new stake in Syros Pharmaceuticals during the fourth quarter worth $92,000. Hedge funds and other institutional investors own 97.17% of the company’s stock.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.

Read More: Ex-Dividend

Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.